StreetAlpha
13F holdings · Q3 2026

Propel Bio Management

Los Angeles, CA · files as Propel Bio Management, LLC
Know the moment Propel Bio Management filesYou follow Propel Bio Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 1969764

Propel Bio Management reported 30 stocks worth $189M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PAGP (17.5%), ACHV (16.6%) and DCTH (5.1%). Compared with Q2 2026, the fund opened new positions in COLL, CABA and PROK, added to MIST, PHAT and MAZE, trimmed ACHV, DCTH and CORT and sold out of ZVRA, EYPT and SLN.

Latest filing: what Propel Bio Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
5 new5 added15 trimmed4 sold outBought about $27.4M · sold about $65.1M
New 5
Added 5
Trimmed 15
See all 15 →
Sold out 4

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$189M−1.3% vs last quarter
Stocks held305 new · 4 sold out
Top 5 weight48.5%fairly concentrated
Turnover49%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
PAGP
Plains GP Hldgs L P
$33M17.5%1.3MNo change8 of 8
2
ACHV
Achieve Life Sciences Inc
$31.3M16.6%3.9M−170K (−4%)8 of 8
3
DCTH
Delcath Sys Inc
$9.7M5.1%605K−267K (−31%)8 of 8
4
COLL
Collegium Pharmaceutical Inc
$9M4.8%410KNew position1 of 8
5
CORT
Corcept Therapeutics Inc
$8.7M4.6%75K−61K (−45%)3 of 8
6
AQST
Aquestive Therapeutics Inc
$8.6M4.6%279K−1.2M (−81%)3 of 8
7
MIST
Milestone Pharmaceuticals in
$8.2M4.3%9.4M+2M (+27%)7 of 8
8
PHAT
Phathom Pharmaceuticals Inc
$8.1M4.3%1.1M+56K (+5%)8 of 8
9
CMPS
Compass Pathways PLC
$6.8M3.6%549K−24K (−4%)6 of 8
10
OBIO
Orchestra Biomed Hldgs Inc
$5.6M3.0%897KNo change3 of 8
🔒 20 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
ZVRA
Zevra Therapeutics Inc
$3.6M254K
EYPT
Eyepoint Pharmaceuticals Inc
$2.7M192K
SLN
Silence Therapeutics PLC
$2.1M192K
SGMT
Sagimet Biosciences Inc
$973K126K

Reported value

last 8 quarters
$101MQ4 '24
$86.1MQ1 '25
$82.4MQ2 '25
$99.9MQ3 '25
$117MQ4 '25
$159MQ1 '26
$191MQ2 '26
$189MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Propel Bio Management 13F FAQ

What does Propel Bio Management own?

Propel Bio Management reported 30 stocks worth $189M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PAGP (17.5%), ACHV (16.6%) and DCTH (5.1%). The table above lists every position in the filing (the top 10 without an account).

What did Propel Bio Management buy and sell in Q3 2026?

Compared with Q2 2026: 5 new positions, 5 added to, 15 trimmed and 4 sold out. New positions include COLL, CABA and PROK. It sold all of ZVRA, EYPT and SLN.

When will Propel Bio Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Propel Bio Management's portfolio worth?

The Q3 2026 filing reports $189M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.